what was the first glp 1 drug Reflections on discovery GLP-1 as a satiety hormone: Implications for obesity therapy and future directions World Health Organization issues first-ever

We believe these data underscore the potential of CagriSema to address unmet medical needs in obesity and support long-term disease management." The NDA is based on results from REDEFINE 1, a 68-week, phase 3, randomized, double-blind, placebo-and active-controlled trial that evaluated the efficacy and safety of once-weekly CagriSema compared to semaglutide 2.4 mg alone, cagrilintide 2.4 mg alone, or placebo, all as an adjunct to lifestyle intervention in 3,417 adults with obesity (BMI 30 kg/m 2 ) or overweight (BMI 27 kg/m 2 ) with one or more obesity-related complications and without diabetes, and REDEFINE 2, a double-blind, randomized, placebo-controlled, 68-week, phase 3 trial that evaluated the efficacy and safety of once-weekly CagriSema versus placebo, as an adjunct to lifestyle intervention in 1,206 adults with type 2 diabetes and either obesity (BMI 30 kg/m 2 ) or overweight (BMI 27 kg/m 2 )

It plays a crucial role in preventing nerve damage by forming a protective layer (myelin) around nerves, making it beneficial for conditions like neuropathy

together they address overlapping stages of healing

L-carnitine is ook geassocieerd met verbeteringen bij patinten met ernstige hartaandoeningen, zoals coronaire hartziekte en chronisch hartfalen (40, 41)

Deyo RA, Cherkin DC, Ciol MA

Of note, only four of the articles specifically indicated that the initial 120 weeks of GLP-1 RA treatment was associated with an increase in retained gastric contents, with the highest increase within the first 12 weeks (Ushakumari and Sladen 2024